Dental Treatment Information

2021 Archives

	Still Protected! Medicare's Six Protected Drug Classes Policy Survives Trump's Attack ADAP Advocacy Association \| April 29, 2021
	Revisions to the Trogarzo (ibalizumab-uiyk) product labeling FDA \| April 26, 2021
	CANN Celebrates Biden Administration Protecting Medicare Part D Community Access national Network \| March 2021
	Certain HIV Meds May Trigger Weight Gain WebMD \| March 16, 2021
	Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV Business Wire \| March 15, 2021
	Another HIV Tivicay Birth Outcome: Better Infant Survival Medscape \| MARCH 15, 2021
	PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund). ADAP \| MARCH 11, 2021
	CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI NATAP \| CROI 2021 March 6-10
	CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254 NATAP \| CROI 2021 March 6-10
	CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE NATAP \| CROI 2021 March 6-10
	CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS NATAP \| CROI 2021 March 6-10

	CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS NATAP \| CROI 2021 March 6-10
	CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR NATAP \| CROI 2021 March 6-10
	CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH NATAP \| CROI 2021 March 6-10
	Revisions to TRIUMEQ and DOVATO labeling FDA \| March 2, 2021
	Op-ed: Six Protected Classes and Protecting People with HIV plus \| February 26, 2021
	ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months ViiV Healthcare \| February 24, 2021
	Ask the Doctors: New HIV treatment administered monthly Lompoc Record \| February 18, 2021
	FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection ViiV Healthcare \| January 21, 2021
	MAT Provides Patients with More Transparency Around Medicine Costs ADAP Advocacy Association \| January 21, 2021 Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).
	Tivicay approved in Europe in new dispersible tablet for children with HIV pharmaphorum \| January 14, 2021
	Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries Infectious Disease Advisor \| January 11, 2021
	Many health plans now must cover full cost of expensive HIV prevention drugs Duluth News Tribune \| January 10, 2021